NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Revenue (TTM): 4.417M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.417M |
| September 30, 2023 | 22.43M |
| June 30, 2023 | 29.76M |
| March 31, 2023 | 36.63M |
| December 31, 2022 | 55.33M |
| September 30, 2022 | 58.11M |
| June 30, 2022 | 68.78M |
| March 31, 2022 | 77.26M |
| December 31, 2021 | 77.88M |
| September 30, 2021 | 76.69M |
| June 30, 2021 | 81.60M |
| Date | Value |
|---|---|
| March 31, 2021 | 84.58M |
| December 31, 2020 | 87.37M |
| September 30, 2020 | 98.68M |
| June 30, 2020 | 96.77M |
| March 31, 2020 | 102.36M |
| December 31, 2019 | 103.54M |
| September 30, 2019 | 119.58M |
| June 30, 2019 | 118.83M |
| March 31, 2019 | 115.60M |
| December 31, 2018 | 108.66M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
4.417M
Minimum
Dec 2023
119.58M
Maximum
Sep 2019
73.72M
Average
77.88M
Median
Dec 2021
Revenue (TTM) Benchmarks
| Catalent Inc | 4.135B |
| AIM ImmunoTech Inc | 0.202M |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 59.65M |
| Armata Pharmaceuticals Inc | -- |